-
Which Covid-19 vaccines look likely to be the best bets?
News The race to produce a treatment to prevent Covid-19 has hundreds of entrants. How should investors approach it? Matthew Partridge reports.
News -
The race to defeat the superbugs has just begun
Analysis Drug-resistant bacteria are far more dangerous than Covid-19. So will we soon see major progress in developing new antibiotics? It will be a long slog, says Ben Judge.
Analysis -
Gilead's takeover of Forty Seven should soothe shareholders' worries
News Gilean, the biopharma giant, is stocking up on potentially lucrative cancer drugs by snapping up smaller operators.
News -
The drugs don’t work: stopping the spread of the superbugs
Cover Story Antibiotic resistance could turn medical inconveniences into death sentences and become a bigger killer than cancer. Governments and pharmaceutical companies are fighting back. Sarah Moore reports.
Cover Story -
If you'd invested in: GW Pharmaceuticals and Trinity Mirror
Features GW Pharmaceuticals makes medicine from cannabis, while Trinity Mirror is the country’s biggest newspaper, magazine and digital publisher.
Features -
Hikma Pharmaceuticals upgrades 2013 revenue outlook
News Shares in Hikma Pharmaceuticals rose Thursday after the company upgraded its 2013 revenue growth forecast following a "strong start to the year".
News -
Three cheap pharma stocks to buy now
Features Look for reasonably-valued pharmas to grow your portfolio, says professional stock picker Samuel D Isaly. Here, he tips three such stocks to buy now.
Features -
Nanotechnology fuels Oxford Instruments profit rise
News High-tech tools maker Oxford Instruments said it made good progress in the first half driven by new product introductions and global demand for Nanotech tools.
News -
British biotech takes off
Features With a catalogue of exciting breakthroughs, the most exciting story for penny investors this year has been biotechnology, says Tom Bulford.
Features
